A novel treatment for Riehl's melanosis targeting both dermal melanin and vessels

Abstract

AbstractBackground/purposeRiehl's melanosis is a difficult‐to‐treat condition characterized by persisting dermal hyperpigmentation. This study aimed to evaluate the efficacy of a histology‐specific targeted therapy for Riehl's melanosis.MethodsSkin biopsy samples of Riehl's melanosis were assessed to identify histology‐specific targets for treatment. Subsequently, the efficacy of a combination involving a fractional picosecond laser and a pulsed dye laser (PDL) targeting the dermal melanin and vessels, respectively, was evaluated. Clinical improvement was assessed using the dermal pigmentation area and severity index (DPASI). The treatment outcomes were compared to those of a control, in this case a single laser treatment solely targeting pigmentation.ResultsHistological and immunohistochemical analyses identified dermal melanin pigment and dilated vessels as treatment targets for Riehl's melanosis. The combined treatment of the fractional picosecond laser and PDL showed a significant reduction of the DPASI scores, which was significantly better than the control group. Patients who underwent the combined laser treatment indicated high levels of satisfaction with no adverse events except of transient erythema and oedema.ConclusionThe combined treatment of a fractional picosecond laser and a PDL was more effective for Riehl's melanosis compared to single laser treatment. The treatment targets both dermal pigmentation and dilated vessels, offering promising results for those working to manage Riehl's melanosis.